Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Employees

1,837

Sector

Biotechnology & Medical Research

Calendar

01/09 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
10/07/25	335.80 $	-4.00%	371,200
09/07/25	349.80 $	+1.98%	373,200
08/07/25	343.00 $	-2.67%	485,879
07/07/25	352.40 $	-2.65%	330,200
04/07/25	362.00 $	+3.61%	784,735

Delayed Quote Hong Kong S.E., 10 July 2025 at 06:08 pm AEST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

349.80HKD

Average target price

321.97HKD

Spread / Average Target

-7.95%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 06:08:14 10/07/25 pm AEST			5-day change	1st Jan Change
335.80 ^HKD	-4.00%		-3.89%	+105.63%

12/06	SKB Biopharma Raises HK$1.94 Billion from Share Placement	MT
12/06	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives A Clinical Trial Notice Approving the Investigational New Drug Application for the Its CLDN18.2-Directed Antibody-Drug Conjugate SKB315 in Combination of the Anti-Programmed Death Ligand 1 (PD-L1) Monoclonal Antibody Tagitanlimab	CI

Capitalization	70.19B 76.75B 9.78B 8.35B 7.78B 7.2B 13.4B 838B 14.98B 93.15B 35.44B 392B 36.67B 35.91B 1,433B	P/E ratio 2025 *	-117x	P/E ratio 2026 *	-820x
Enterprise value	68.8B 75.22B 9.58B 8.19B 7.63B 7.05B 13.13B 821B 14.68B 91.3B 34.74B 384B 35.94B 35.2B 1,404B	EV / Sales 2025 *	34.9x	EV / Sales 2026 *	22.5x
Free-Float	59.59%	Yield 2025 *	-	Yield 2026 *	-

SKB Biopharma Raises HK$1.94 Billion from Share Placement	12/06	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives A Clinical Trial Notice Approving the Investigational New Drug Application for the Its CLDN18.2-Directed Antibody-Drug Conjugate SKB315 in Combination of the Anti-Programmed Death Ligand 1 (PD-L1) Monoclonal Antibody Tagitanlimab	12/06	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination with Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer	11/06	CI
Sichuan Kelun-Biotech Lung Cancer Combo Gets Breakthrough Tag in China; Shares Slide 3%	11/06	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results from Phase 1/2 Study of Kelun-Biotech's Trop2 Adc Sacituzumab Tirumotecan	11/06	CI
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC	07/06	CI
SKB Biopharmaceutical Seeks to Raise HK$1.94 Billion from Share Placement; Shares Fall 7%	05/06	MT
Sichuan Kelun-Biotech Biopharmaceutical Placing 5.9 Mln Placing H Shares At HK$331.8 Per Placing H Share	05/06	RE
Accelerated Bookbuild Offering Of H Shares In Sichuan Kelun-Biotech Biopharmaceutical, Term Sheet Shows	04/06	RE
Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. to Present Results from Six Clinical Studies	23/05	CI
SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract	23/05	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives an Upfront Payment from Windward Bio AG	23/05	CI
Chinese Regulator Accepts SKB Biopharma's New Indication Application for Breast Cancer Drug	22/05	MT

Jefferies Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$300 from HK$240, Keeps at Buy	26/03	MT
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy	18/02	MT
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$195.51 From HK$196.40, Keeps at Buy	20/08/24	MT

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock

Equities

6990

CNE1000062J1

Biotechnology & Medical Research

Valuation: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Chart: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Latest news: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Analysts' recommendations: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Press Releases: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024	26/03	PR
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).	11/01	PR

1 day	-4.00%
1 week	-3.89%
Current month	+2.63%
1 month	-3.89%
3 months	+19.59%
6 months	+103.02%
Current year	+105.63%

1 week	333.8	369.8
1 month	314.2	380
Current year	153.9	380
1 year	120.2	380
3 years	60.6	380
5 years	60.6	380
10 years	60.6	380

Manager	Title	Age	Since
Jun You Ge CEO	Chief Executive Officer	53	01/03/2022
Ze Jian Zhou DFI	Director of Finance/CFO	42	17/08/2022
Xiao Ping Jin CTO	Chief Tech/Sci/R&D Officer	48	06/09/2021

Director	Title	Age	Since
Ge Xin Liu CHM	Chairman	74	01/03/2022
Jun You Ge BRD	Director/Board Member	53	25/02/2022
Si Chuan Liu BRD	Director/Board Member	41	22/11/2016

	2025 *	2026 *
Net sales	1.97B 2.16B 275M 235M 219M 202M 377M 23.56B 421M 2.62B 996M 11.01B 1.03B 1.01B 40.28B	3.05B 3.33B 425M 363M 338M 313M 582M 36.41B 651M 4.05B 1.54B 17.01B 1.59B 1.56B 62.23B
Net income	-612M -669M -85.26M -72.83M -67.87M -62.77M -117M -7.31B -131M -812M -309M -3.41B -320M -313M -12.49B	-79.64M -87.07M -11.09M -9.47M -8.83M -8.17M -15.2M -951M -16.99M -106M -40.21M -444M -41.6M -40.74M -1.63B
Net Debt	-1.39B -1.52B -194M -166M -154M -143M -266M -16.62B -297M -1.85B -703M -7.76B -727M -712M -28.4B	-1.5B -1.64B -208M -178M -166M -153M -285M -17.86B -319M -1.98B -755M -8.34B -781M -765M -30.53B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-4.00%	-3.89%	+153.05%	-	10.18B
ARGENX SE	+2.34%	+3.50%	+10.71%	+32.36%	33.32B
WUXI APPTEC CO., LTD.	-0.99%	-0.71%	+87.06%	-36.75%	27.79B
BIONTECH SE	+0.14%	+2.03%	+38.04%	-32.58%	27.52B
SUMMIT THERAPEUTICS INC.	-0.46%	+1.02%	+199.16%	+2,380.00%	18.37B
INSMED INCORPORATED	-0.57%	-2.26%	+30.77%	+310.26%	18.32B
WUXI BIOLOGICS (CAYMAN) INC.	-0.77%	-0.39%	+141.09%	-66.65%	13.43B
GENMAB A/S	+0.84%	+6.89%	-21.76%	-44.69%	13.23B
AKESO, INC.	-1.37%	+2.07%	+189.96%	+364.81%	12.55B
EXELIXIS, INC.	+0.50%	-4.32%	+100.25%	+114.03%	12.02B
Average	-0.44%	+4.12%	+92.83%	+335.64%	18.67B
Weighted average by Cap.	-0.08%	+3.08%	+79.26%	+300.41%